Biogen Idec Awarded Summary Judgment in N.Y. Federal Tysabri Action

BUFFALO, N.Y. — A New York federal judge has awarded Biogen Idec Inc. summary judgment in a Tysabri action, ruling that the warnings accompanying the MS drug sufficiently apprised physicians of the risk of progressive multifocal leukoencephalopathy (PML).

On April 10, Judge Michael A. Telesca of the U.S. District Court for the Western District of New York further held that the claims are preempted because there is “smoking gun” evidence that the Food and Drug Administration would have rejected the warning suggested by plaintiff.

In 2005, Andrea Amos was diagnosed with MS. She began taking Tysabri, an immunosuppressant, in 2006 …